Patents by Inventor Glenn Alan Meyer

Glenn Alan Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulations
    Patent number: 6316020
    Abstract: Pharmaceutical compositions and formulations comprised of one or more active ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof combined with at least one cyclodextrin.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: November 13, 2001
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall, Glenn Alan Meyer
  • Method of improving bioavailability
    Patent number: 6312712
    Abstract: Improved bioavailability method of one or more of certain pharmaceutically active compounds or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof that include administering a non-toxic, therapeutically effective amount of the compounds combined with at least one cyclodextrin to a mammal in need of treatment of gastric acid related diseases.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: November 6, 2001
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall, Glenn Alan Meyer
  • Pharmaceutical unit dosage form
    Patent number: 6312723
    Abstract: Pharmaceutical formulations, in oral unit dosage forms, have one or more active ingredients or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof combined with at least one cyclodextrin.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: November 6, 2001
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall, Glenn Alan Meyer, Steven A. Fontana
  • Pharmaceutical formulation
    Patent number: 6245352
    Abstract: The present invention relates to a pharmaceutical formulation, which comprises from 5 to 15% by weight of tamoxifen citrate and a first disintegrant which is croscarmellose sodium, the percentage by weight of croscarmellose sodium present in the formulation being chosen such that, in six 20 mg unit doses, an average of at least 65 percent by weight of the tamoxifen citrate in the formulation will dissolve within 10 minutes in 1000 mL of 0.02N hydrochloric acid at 37° C. when stirred at 100 rpm.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: June 12, 2001
    Assignee: Eli Lilly and Company
    Inventors: Gordon Nelson Arbuthnot, Karen Klapper Lomas, Glenn Alan Meyer